deruxtecan - Robuta Search

https://www.enhertuhcp.com/en ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official HCP Site Discover ENHERTU, an FDA-approved treatment option. See Prescribing Information, including Boxed WARNINGS. trastuzumab deruxtecan fam official hcp site https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-enhertu-fam-trastuzumab-deruxtecan-nxki-unresectable-or FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for... Listen to a soundcast of the April 5, 2024, FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447&r=1 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive... Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable... https://www.businesswire.com/news/home/20260413512111/en/Ifinatamab-Deruxtecan-Granted-Priority-Review-in-the-U.S.-for-Adult-Patients-with-Previously-Treated-Extensive-Stage-Small-Cell-Lung-Cancer-who-Experienced-Disease-Progression-on-or-After-Platinum-Based-Chemotherapy Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously... I-DXd BLA Acceptance https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trastuzumab-deruxtecan Definition of fam-trastuzumab deruxtecan-nxki - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of trastuzumab deruxtecan fam nci drug https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-trastuzumab-deruxtecan-for-cancers-that-have-a-large-amount-of-her2-destiny-pantumour02 A trial of trastuzumab deruxtecan for cancers that have a large amount of HER2 (DESTINY-PanTumour02) This trial was looking at trastuzumab deruxtecan for cancers that had a high number of HER2 receptors (HER2). https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive... Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-datopotamab-deruxtecan-durvalumab-advanced-triple-negative-breast-cancer-diamond A trial looking at datopotamab deruxtecan and durvalumab for advanced triple negative breast cancer... This trial is comparing datopotamab deruxtecan with durvalumab and datopotamab deruxtecan for triple negative breast cancer. https://medicine.yale.edu/cancer/trial/a-study-of-raludotatug-deruxtecan-r-dxd-in-subjects-with-platinum-resistant-high-grade-ovarian-p/ A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed... This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer. https://www.enhertu.com/ ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information. trastuzumab deruxtecan fam official patient https://adisinsight.springer.com/drugsafety/803927214?error=cookies_not_supported&code=3a8e6b58-e49e-4054-a427-7ff90d3ddf18 Datopotamab deruxtecan - AdisInsight Six patients [ages and sexes not stated] with EGFR-mutated advanced non-small-cell lung cancer and progressive disease on first-line osimertinib received oral datopotamab deruxtecan adisinsight https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-rilvegostomig-trastuzumab-deruxtecan-advanced-stomach-gastro-oesophageal-junction-cancer-artemide-gastric-01 A trial looking at rilvegostomig and trastuzumab deruxtecan for advanced stomach or gastro... This trial is looking at rilvegostomig and trastuzumab deruxtecan for cancer that has spread. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic... On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult... https://experts.umn.edu/en/projects/a-phase-1b2-multicenter-open-label-study-of-ifinatamab-deruxtecan/ A Phase 1B/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), A B7- H3... https://health.economictimes.indiatimes.com/tag/patritumab+deruxtecan Patritumab deruxtecan - Latest patritumab deruxtecan , Information & Updates - Health -ET... ETHealthworld.com brings latest patritumab deruxtecan news, views and updates from all top sources for the Indian Health industry. latest information updates health et https://www.businesswire.com/news/home/20240402075330/en/REJOICE-Ovarian01-Phase-23-Trial-of-Raludotatug-Deruxtecan-Initiated-in-Patients-with-Platinum-Resistant-Ovarian-Cancer REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with... REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09124 Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable,... Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable, Locally Advanced or Metastatic Breast Cancer datopotamab deruxtecan for the trastuzumab https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/ Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer - PMC Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of... advanced breast cancer trastuzumab deruxtecan previously treated https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-datopotamab-deruxtecan-and-durvalumab-for-breast-cancer-tropion-breast04 A trial looking at datopotamab deruxtecan and durvalumab for breast cancer (TROPION-Breast04) This trial is comparing datopotamab deruxtecan and durvalumab with pembrolizumab and standard chemotherapy before surgery for breast cancer. https://pubmed.ncbi.nlm.nih.gov/41835339/ Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer:... In this large national real-world cohort from an LMIC, T-DXd demonstrated robust antitumor activity and a manageable safety profile in patients with HER2+ mBC.... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-trastuzumab-deruxtecan-for-breast-cancer-destiny-breast07 A study looking at trastuzumab deruxtecan for breast cancer (DESTINY-breast07) This study is looking at trastuzumab deruxtecan by itself and with other cancer drugs for breast cancer. a study looking at trastuzumab deruxtecan breast cancer https://pubmed.ncbi.nlm.nih.gov/39841861/ Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in... HER2 loss and decrease in HER2 expression are common in patients with MBC receiving treatment with T-DXd. Reevaluation of HER2 status following T-DXd treatment... epidermal growth factor